← Back to headlines
AbbVie Reportedly Nearing $10.9 Billion Acquisition of Apogee Therapeutics
AbbVie is reportedly close to acquiring Apogee Therapeutics in a deal valued at $10.9 billion, which would provide AbbVie with an experimental eczema drug.
20 Jun, 11:56 — 20 Jun, 16:11
The Story
Analyzing sources…
Source Diversity
Source Diversity
Moderate (27/100)2 sources— more sources would strengthen this score15/33
Spectrum spread— 2/5 buckets covered8/33
Far L
Left
Center1
Center (1)
marketwatch
Right1
Right (1)
seeking-alpha
Far R
Geographic diversity— 1 region4/34
US2
ℹAll sources from US region
ℹOnly 2 sources cover this story
Sources
Showing 2 of 2 sources
marketwatchMostly Factual49d ago
AbbVie would gain an experimental eczema drug by buying biotech: report
AbbVie is reportedly trying to buy a biotech company that is developing a promising atopic dermatitis drug for $10.9 billion in cash, according to a Financial Times report.
By Jaimy Lee
Read full article →seeking-alphaMixed50d ago
AbbVie said to be nearing a $10.9B deal to buy Apogee Therapeutics
Read full article →Coverage Timeline
First report: seeking-alpha · 20 Jun, 11:56|Full coverage: 2 · 4h|Window: 4h
Left-leaningCenterRight-leaning
